Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2012 Sep 12;28(5):631–640. doi: 10.1007/s12264-012-1270-2

Mitochondrial dysfunction and cellular metabolic deficiency in Alzheimer’s disease

Xue-Mei Gu 1, Han-Chang Huang 2,3, Zhao-Feng Jiang 2,✉
PMCID: PMC5561922  PMID: 22968595

Abstract

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder. The pathology of AD includes amyloid-β (Aβ) deposits in neuritic plaques and neurofibrillary tangles composed of hyperphosphorylated tau, as well as neuronal loss in specific brain regions. Increasing epidemiological and functional neuroimaging evidence indicates that global and regional disruptions in brain metabolism are involved in the pathogenesis of this disease. Aβ precursor protein is cleaved to produce both extracellular and intracellular Aβ, accumulation of which might interfere with the homeostasis of cellular metabolism. Mitochondria are highly dynamic organelles that not only supply the main energy to the cell but also regulate apoptosis. Mitochondrial dysfunction might contribute to Aβ neurotoxicity. In this review, we summarize the pathways of Aβ generation and its potential neurotoxic effects on cellular metabolism and mitochondrial dysfunction.

Keywords: Alzheimer’s disease, amyloid-β, metabolic deficiency, mitochondrial dysfunction

References

  • [1].Huang H.C., Jiang Z.F. Amyloid-beta protein precursor family members: a review from homology to biological function. J Alzheimers Dis. 2011;26:607–626. doi: 10.3233/JAD-2011-110335. [DOI] [PubMed] [Google Scholar]
  • [2].Huang H.C., Jiang Z.F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer’s disease. J Alzheimers Dis. 2009;16:15–27. doi: 10.3233/JAD-2009-0960. [DOI] [PubMed] [Google Scholar]
  • [3].Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. Lancet Neurol. 2011;10:187–198. doi: 10.1016/S1474-4422(10)70277-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4].Sultana R., Mecocci P., Mangialasche F., Cecchetti R., Baglioni M., Butterfield D.A. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer’s disease: insights into the role of oxidative stress in Alzheimer’s disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis. 2011;24:77–84. doi: 10.3233/JAD-2011-101425. [DOI] [PubMed] [Google Scholar]
  • [5].Ishii K., Sasaki M., Kitagaki H., Yamaji S., Sakamoto S., Matsuda K., et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease. J Nucl Med. 1997;38:925–928. [PubMed] [Google Scholar]
  • [6].Kennedy A.M., Frackowiak R.S., Newman S.K., Bloomfield P.M., Seaward J., Roques P., et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neurosci Lett. 1995;186:17–20. doi: 10.1016/0304-3940(95)11270-7. [DOI] [PubMed] [Google Scholar]
  • [7].Furst A.J., Lal R.A. Amyloid-beta and glucose metabolism in Alzheimer’s disease. J Alzheimers Dis. 2011;26(Suppl3):105–116. doi: 10.3233/JAD-2011-0066. [DOI] [PubMed] [Google Scholar]
  • [8].Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490:115–125. doi: 10.1016/j.ejphar.2004.02.049. [DOI] [PubMed] [Google Scholar]
  • [9].Young-Collier K.J., McArdle M., Bennett J.P. The dying of the light: mitochondrial failure in Alzheimer’s disease. J Alzheimers Dis. 2012;28:771–781. doi: 10.3233/JAD-2011-111487. [DOI] [PubMed] [Google Scholar]
  • [10].Liang W.S., Reiman E.M., Valla J., Dunckley T., Beach T.G., Grover A., et al. Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A. 2008;105:4441–4446. doi: 10.1073/pnas.0709259105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Selfridge JE, E L, Lu J, Swerdlow RH. Role of mitochondrial homeostasis and dynamics in Alzheimer’s disease. Neurobiol Dis 2012, doi:10.1016/j.nbd.2011.12.057. [DOI] [PMC free article] [PubMed]
  • [12].Sheng B., Wang X., Su B., Lee H.G., Casadesus G., Perry G., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem. 2012;120:419–429. doi: 10.1111/j.1471-4159.2011.07581.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Carey R.M., Balcz B.A., Lopez-Coviella I., Slack B.E. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 2005;6:30. doi: 10.1186/1471-2121-6-30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Koo E.H., Squazzo S.L., Selkoe D.J., Koo C.H. Trafficking of cell surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci. 1996;109(Pt5):991–998. doi: 10.1242/jcs.109.5.991. [DOI] [PubMed] [Google Scholar]
  • [15].Yamazaki T., Koo E.H., Selkoe D.J. Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. J Cell Sci. 1996;109(Pt5):999–1008. doi: 10.1242/jcs.109.5.999. [DOI] [PubMed] [Google Scholar]
  • [16].Pasternak S.H., Bagshaw R.D., Guiral M., Zhang S., Ackerley C.A., Pak B.J., et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem. 2003;278:26687–26694. doi: 10.1074/jbc.M304009200. [DOI] [PubMed] [Google Scholar]
  • [17].Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer’s disease. Mol Brain. 2011;4:3. doi: 10.1186/1756-6606-4-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Greenfield J.P., Tsai J., Gouras G.K., Hai B., Thinakaran G., Checler F., et al. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci U S A. 1999;96:742–747. doi: 10.1073/pnas.96.2.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Annaert W.G., Levesque L., Craessaerts K., Dierinck I., Snellings G., Westaway D., et al. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol. 1999;147:277–294. doi: 10.1083/jcb.147.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Verdier Y., Zarandi M., Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer’s disease. J Pept Sci. 2004;10:229–248. doi: 10.1002/psc.573. [DOI] [PubMed] [Google Scholar]
  • [21].Caltagarone J., Jing Z., Bowser R. Focal adhesions regulate Abeta signaling and cell death in Alzheimer’s disease. Biochim Biophys Acta. 2007;1772:438–445. doi: 10.1016/j.bbadis.2006.11.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22].Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15–20. doi: 10.1016/S0002-9440(10)64700-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Kaminski Schierle G.S., van de Linde S., Erdelyi M., Esbjorner E.K., Klein T., Rees E., et al. In situ measurements of the formation and morphology of intracellular beta-amyloid fibrils by super-resolution fluorescence imaging. J Am Chem Soc. 2011;133:12902–12905. doi: 10.1021/ja201651w. [DOI] [PubMed] [Google Scholar]
  • [24].Gyure K.A., Durham R., Stewart W.F., Smialek J.E., Troncoso J.C. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001;125:489–492. doi: 10.5858/2001-125-0489-IAAPDO. [DOI] [PubMed] [Google Scholar]
  • [25].Knobloch M., Konietzko U., Krebs D.C., Nitsch R.M. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007;28:1297–1306. doi: 10.1016/j.neurobiolaging.2006.06.019. [DOI] [PubMed] [Google Scholar]
  • [26].Mohamed A., Posse de Chaves E. Abeta internalization by neurons and glia. Int J Alzheimers Dis. 2011;2011:127984. doi: 10.4061/2011/127984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Tampellini D., Rahman N., Lin M.T., Capetillo-Zarate E., Gouras G.K. Impaired beta-amyloid secretion in Alzheimer’s disease pathogenesis. J Neurosci. 2011;31:15384–15390. doi: 10.1523/JNEUROSCI.2986-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Tampellini D., Rahman N., Gallo E.F., Huang Z., Dumont M., Capetillo-Zarate E., et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci. 2009;29:9704–9713. doi: 10.1523/JNEUROSCI.2292-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–421. doi: 10.1016/S0896-6273(03)00434-3. [DOI] [PubMed] [Google Scholar]
  • [30].Bayer T.A., Wirths O. Intracellular accumulation of amyloid-Beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease. Front Aging Neurosci. 2010;2:8. doi: 10.3389/fnagi.2010.00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Langui D., Girardot N., El Hachimi K.H., Allinquant B., Blanchard V., Pradier L., et al. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol. 2004;165:1465–1477. doi: 10.1016/S0002-9440(10)63405-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Borger E., Aitken L., Muirhead K.E., Allen Z.E., Ainge J.A., Conway S.J., et al. Mitochondrial beta-amyloid in Alzheimer’s disease. Biochem Soc Trans. 2011;39:868–873. doi: 10.1042/BST0390868. [DOI] [PubMed] [Google Scholar]
  • [33].Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med. 2008;14:45–53. doi: 10.1016/j.molmed.2007.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Yan S.D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F., et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer’s disease. Nature. 1997;389:689–695. doi: 10.1038/39522. [DOI] [PubMed] [Google Scholar]
  • [35].Oppermann U.C., Salim S., Tjernberg L.O., Terenius L., Jornvall H. Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer’s disease. FEBS Lett. 1999;451:238–242. doi: 10.1016/S0014-5793(99)00586-4. [DOI] [PubMed] [Google Scholar]
  • [36].Yan S.D., Stern D.M. Mitochondrial dysfunction and Alzheimer’s disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD) Int J Exp Pathol. 2005;86:161–171. doi: 10.1111/j.0959-9673.2005.00427.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004;304:448–452. doi: 10.1126/science.1091230. [DOI] [PubMed] [Google Scholar]
  • [38].Yao J., Du H., Yan S., Fang F., Wang C., Lue L.F., et al. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31:2313–2320. doi: 10.1523/JNEUROSCI.4717-10.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Lee H.P., Pancholi N., Esposito L., Previll L.A., Wang X., Zhu X., et al. Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PLoS One. 2012;7:e28033. doi: 10.1371/journal.pone.0028033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40].Mao P., Reddy P.H. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011;1812:1359–1370. doi: 10.1016/j.bbadis.2011.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer’s disease. Biochim Biophys Acta. 2010;1801:924–929. doi: 10.1016/j.bbalip.2010.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [42].Grimm S., Hoehn A., Davies K.J., Grune T. Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res. 2011;45:73–88. doi: 10.3109/10715762.2010.512040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [43].Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging. 2011;32:763–777. doi: 10.1016/j.neurobiolaging.2009.04.016. [DOI] [PubMed] [Google Scholar]
  • [44].Williams T.I., Lynn B.C., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer’s disease. Neurobiol Aging. 2006;27:1094–1099. doi: 10.1016/j.neurobiolaging.2005.06.004. [DOI] [PubMed] [Google Scholar]
  • [45].Bradley M.A., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med. 2010;48:1570–1576. doi: 10.1016/j.freeradbiomed.2010.02.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [46].McGarth L.T., McGleenon B.M., Brennan S., McColl D., McIlroy S., Passmore A.P. Increased oxidative stress in Alzheimer’s disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM. 2001;94:485–490. doi: 10.1093/qjmed/94.9.485. [DOI] [PubMed] [Google Scholar]
  • [47].Nam D.T., Arseneault M., Murthy V., Ramassamy C. Potential role of acrolein in neurodegeneration and in Alzheimer’s disease. Curr Mol Pharmacol. 2010;3:66–78. doi: 10.2174/1874467211003020066. [DOI] [PubMed] [Google Scholar]
  • [48].Perluigi M., Sultana R., Cenini G., Di Domenico F., Memo M., Pierce W.M., et al. Redox proteomics identification of 4-hydroxynonenalmodified brain proteins in Alzheimer’s disease: Role of lipid peroxidation in Alzheimer’s disease pathogenesis. Proteomics Clin Appl. 2009;3:682–693. doi: 10.1002/prca.200800161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [49].Mark R.J., Pang Z., Geddes J.W., Uchida K., Mattson M.P. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci. 1997;17:1046–1054. doi: 10.1523/JNEUROSCI.17-03-01046.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Gwon AR, Park JS, Arumugam TV, Kwon YK, Chan SL, Kim SH, et al. Oxidative lipid modification of nicastrin enhances amyloidogenic gamma-secretase activity in Alzheimer’s disease. Aging Cell 2012, doi: 10.1111/j.1474-9726.2012.00817.x. [DOI] [PMC free article] [PubMed]
  • [51].Pocernich C.B., Butterfield D.A. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer’s disease. Neurotox Res. 2003;5:515–520. doi: 10.1007/BF03033161. [DOI] [PubMed] [Google Scholar]
  • [52].Lovell M.A., Markesbery W.R. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer’s disease. Nucleic Acids Res. 2007;35:7497–7504. doi: 10.1093/nar/gkm821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [53].Jacobsen E., Beach T., Shen Y., Li R., Chang Y. Deficiency of the Mre11 DNA repair complex in Alzheimer’s disease brains. Brain Res Mol Brain Res. 2004;128:1–7. doi: 10.1016/j.molbrainres.2004.05.023. [DOI] [PubMed] [Google Scholar]
  • [54].Wang J., Xiong S., Xie C., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease. J Neurochem. 2005;93:953–962. doi: 10.1111/j.1471-4159.2005.03053.x. [DOI] [PubMed] [Google Scholar]
  • [55].Baloyannis S.J. Mitochondria are related to synaptic pathology in Alzheimer’s disease. Int J Alzheimers Dis. 2011;2011:305395. doi: 10.4061/2011/305395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [56].de la Monte S.M., Luong T., Neely T.R., Robinson D., Wands J.R. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease. Lab Invest. 2000;80:1323–1335. doi: 10.1038/labinvest.3780140. [DOI] [PubMed] [Google Scholar]
  • [57].Mayer B., Oberbauer R. Mitochondrial regulation of apoptosis. News Physiol Sci. 2003;18:89–94. doi: 10.1152/nips.01433.2002. [DOI] [PubMed] [Google Scholar]
  • [58].Karbowski M. Mitochondria on guard: role of mitochondrial fusion and fission in the regulation of apoptosis. Adv Exp Med Biol. 2010;687:131–142. doi: 10.1007/978-1-4419-6706-0_8. [DOI] [PubMed] [Google Scholar]
  • [59].Soriano M.E., Scorrano L. The interplay between BCL-2 family proteins and mitochondrial morphology in the regulation of apoptosis. Adv Exp Med Biol. 2010;687:97–114. doi: 10.1007/978-1-4419-6706-0_6. [DOI] [PubMed] [Google Scholar]
  • [60].Kasanuki K., Iseki E., Fujishiro H., Yamamoto R., Higashi S., Minegishi M., et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F]_fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci. 2012;314:111–119. doi: 10.1016/j.jns.2011.10.010. [DOI] [PubMed] [Google Scholar]
  • [61].Salek R.M., Xia J., Innes A., Sweatman B.C., Adalbert R., Randle S., et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer’s disease. Neurochem Int. 2010;56:937–947. doi: 10.1016/j.neuint.2010.04.001. [DOI] [PubMed] [Google Scholar]
  • [62].Yates C.M., Butterworth J., Tennant M.C., Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimertype and other dementias. J Neurochem. 1990;55:1624–1630. doi: 10.1111/j.1471-4159.1990.tb04948.x. [DOI] [PubMed] [Google Scholar]
  • [63].Xiang Y., Xu G., Weigel-Van Aken K.A. Lactic acid induces aberrant amyloid precursor protein processing by promoting its interaction with endoplasmic reticulum chaperone proteins. PLoS One. 2010;5:e13820. doi: 10.1371/journal.pone.0013820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [64].Stubbs M., Veech R.L., Krebs H.A. Control of the redox state of the nicotinamide-adenine dinucleotide couple in rat liver cytoplasm. Biochem J. 1972;126:59–65. doi: 10.1042/bj1260059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [65].Zhang Q., Piston D.W., Goodman R.H. Regulation of corepressor function by nuclear NADH. Science. 2002;295:1895–1897. doi: 10.1126/science.1069300. [DOI] [PubMed] [Google Scholar]
  • [66].McKenna M.C., Waagepetersen H.S., Schousboe A., Sonnewald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. Biochem Pharmacol. 2006;71:399–407. doi: 10.1016/j.bcp.2005.10.011. [DOI] [PubMed] [Google Scholar]
  • [67].Huang HC, Xu K, Jiang ZF. Curcumin-mediated neuroprotection against amyloid-beta-induced mitochondrial dysfunction involves the inhibition of GSK-3beta. J Alzheimers Dis 2012, doi: 10.3233/JAD-2012-120688. [DOI] [PubMed]
  • [68].Yang Y., Turner R.S., Gaut J.R. The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Abeta40 and Abeta42 secretion. J Biol Chem. 1998;273:25552–25555. doi: 10.1074/jbc.273.40.25552. [DOI] [PubMed] [Google Scholar]
  • [69].Kudo T., Okumura M., Imaizumi K., Araki W., Morihara T., Tanimukai H., et al. Altered localization of amyloid precursor protein under endoplasmic reticulum stress. Biochem Biophys Res Commun. 2006;344:525–530. doi: 10.1016/j.bbrc.2006.03.173. [DOI] [PubMed] [Google Scholar]
  • [70].Sirover M.A. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta. 1999;1432:159–184. doi: 10.1016/S0167-4838(99)00119-3. [DOI] [PubMed] [Google Scholar]
  • [71].Harada N., Yasunaga R., Higashimura Y., Yamaji R., Fujimoto K., Moss J., et al. Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells. J Biol Chem. 2007;282:22651–22661. doi: 10.1074/jbc.M610724200. [DOI] [PubMed] [Google Scholar]
  • [72].Tarze A., Deniaud A., Le Bras M., Maillier E., Molle D., Larochette N., et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene. 2007;26:2606–2620. doi: 10.1038/sj.onc.1210074. [DOI] [PubMed] [Google Scholar]
  • [73].Tisdale E.J. Glyceraldehyde-3-phosphate dehydrogenase is required for vesicular transport in the early secretory pathway. J Biol Chem. 2001;276:2480–2486. doi: 10.1074/jbc.M007567200. [DOI] [PubMed] [Google Scholar]
  • [74].Butterfield D.A., Hardas S.S., Lange M.L. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer’s disease: many pathways to neurodegeneration. J Alzheimers Dis. 2010;20:369–393. doi: 10.3233/JAD-2010-1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [75].Shalova I.N., Cechalova K., Rehakova Z., Dimitrova P., Ognibene E., Caprioli A., et al. Decrease of dehydrogenase activity of cerebral glyceraldehyde-3-phosphate dehydrogenase in different animal models of Alzheimer’s disease. Biochim Biophys Acta. 2007;1770:826–832. doi: 10.1016/j.bbagen.2007.01.014. [DOI] [PubMed] [Google Scholar]
  • [76].Cumming R.C., Schubert D. Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer’s disease. FASEB J. 2005;19:2060–2062. doi: 10.1096/fj.05-4195fje. [DOI] [PubMed] [Google Scholar]
  • [77].Wang Q., Woltjer R.L., Cimino P.J., Pan C., Montine K.S., Zhang J., et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J. 2005;19:869–871. doi: 10.1096/fj.04-2370com. [DOI] [PubMed] [Google Scholar]
  • [78].Schulze H., Schuler A., Stuber D., Dobeli H., Langen H., Huber G. Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer’s beta-amyloid precursor protein. J Neurochem. 1993;60:1915–1922. doi: 10.1111/j.1471-4159.1993.tb13420.x. [DOI] [PubMed] [Google Scholar]
  • [79].Naletova I., Schmalhausen E., Kharitonov A., Katrukha A., Saso L., Caprioli A., et al. Non-native glyceraldehyde-3-phosphate dehydrogenase can be an intrinsic component of amyloid structures. Biochim Biophys Acta. 2008;1784:2052–2058. doi: 10.1016/j.bbapap.2008.07.013. [DOI] [PubMed] [Google Scholar]
  • [80].Parker W.D., Jr, Parks J., Filley C.M., Kleinschmidt-DeMasters B.K. Electron transport chain defects in Alzheimer’s disease brain. Neurology. 1994;44:1090–1096. doi: 10.1212/WNL.44.6.1090. [DOI] [PubMed] [Google Scholar]
  • [81].Fukuyama R., Hatanpaa K., Rapoport S.I., Chandrasekaran K. Gene expression of ND4, a subunit of complex I of oxidative phosphorylation in mitochondria, is decreased in temporal cortex of brains of Alzheimer’s disease patients. Brain Res. 1996;713:290–293. doi: 10.1016/0006-8993(95)01517-5. [DOI] [PubMed] [Google Scholar]
  • [82].Manczak M., Park B.S., Jung Y., Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004;5:147–162. doi: 10.1385/NMM:5:2:147. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES